| Literature DB >> 25772847 |
Emma E Laing1, Jonathan D Johnston, Carla S Möller-Levet, Giselda Bucca, Colin P Smith, Derk-Jan Dijk, Simon N Archer.
Abstract
The power of the application of bioinformatics across multiple publicly available transcriptomic data sets was explored. Using 19 human and mouse circadian transcriptomic data sets, we found that NR1D1 and NR1D2 which encode heme-responsive nuclear receptors are the most rhythmic transcripts across sleep conditions and tissues suggesting that they are at the core of circadian rhythm generation. Analyzes of human transcriptomic data show that a core set of transcripts related to processes including immune function, glucocorticoid signalling, and lipid metabolism is rhythmically expressed independently of the sleep-wake cycle. We also identify key transcripts associated with transcription and translation that are disrupted by sleep manipulations, and through network analysis identify putative mechanisms underlying the adverse health outcomes associated with sleep disruption, such as diabetes and cancer. Comparative bioinformatics applied to existing and future data sets will be a powerful tool for the identification of core circadian- and sleep-dependent molecules.Entities:
Keywords: Reverb; bioinformatics; clock gene; gene expression; sleep disruption
Mesh:
Substances:
Year: 2015 PMID: 25772847 PMCID: PMC5031210 DOI: 10.1002/bies.201400193
Source DB: PubMed Journal: Bioessays ISSN: 0265-9247 Impact factor: 4.345
Figure 1Number of genes with a circadian expression profile identified for each of the four sleep conditions; A: sleeping in phase with melatonin; B: during acute sleep deprivation after sufficient sleep; C: during acute sleep deprivation after insufficient sleep; D: sleeping out of phase with melatonin). Cartoons indicate when sleep (S) and wake (W) occurred with respect to biological day (sun) and biological night (moon). For each condition, numbers in brackets indicate the number of rhythmic core clock genes. The top‐ten biological processes associated with the genes with a circadian expression profile identified in each comparison listed above, respectively. The % enrichment for each process is listed together with the p‐value. The colour‐coded pie chart segments also represent the % enrichment for each process.
Circadian rhythmicity of core clock genes across human and mouse samples
| Human samples | Mouse samples | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human gene symbol | Mouse gene symbol | Total human lists | Total mouse lists | Percent of all human samples % | Percent of human blood samples % | Percent of all mouse samples % | Percent of all samples % | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
| NR1D1 | Nr1d1 | 6 | 16 | 86 | 75 | 100 | 96 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| NR1D2 | Nr1d2 | 6 | 16 | 86 | 100 | 100 | 96 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PER3 | Per3 | 6 | 15 | 86 | 75 | 94 | 91 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| ARNTL | Arntl | 5 | 16 | 71 | 75 | 100 | 91 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PER2 | Per2 | 5 | 16 | 71 | 75 | 100 | 91 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| PER1 | Per1 | 5 | 15 | 71 | 50 | 94 | 87 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| NPAS2 | Npas2 | 3 | 15 | 43 | 75 | 94 | 78 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| CRY1 | Cry1 | 2 | 13 | 29 | 0 | 81 | 65 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| CLOCK | Clock | 1 | 13 | 14 | 25 | 81 | 61 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| CRY2 | Cry2 | 2 | 10 | 29 | 25 | 63 | 52 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
| CSNK1E | Csnk1e | 5 | 2 | 71 | 100 | 13 | 30 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| RORA | Rora | 2 | 2 | 29 | 50 | 13 | 17 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| CSNK1D | Csnk1d | 1 | 2 | 14 | 25 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Key for samples, 1 indicates rhythmic; 0 indicates arrhythmic; A, Akashi follicle (240 genes); B, Archer D1 (1395 genes); C, Archer D2 (228 genes); D, Hughes (1111 genes); E, Li Human brain (916 genes); F, Moller‐Levet SE (1855 genes); G, Moller‐Levet SR (1480 genes); H, Barclay rhythmic control classes123 (3231 genes); I, Barclay rhythmic TSR classes126 (2461 genes); J, Maret Table3 Control Condition (1654 genes); K, Maret Table4 Sleep Deprivation (340 genes); L, Hogenesch Adrenal gland (1052 genes); M, Hogenesch Aorta (873 genes); N, Hogenesch BrainStem (693 genes); O, Hogenesch Brown fat (1492 genes); P, Hogenesch Cerebellum (726 genes); Q, Hogenesch Heart (1187 genes); R, Hogenesch Hypothalamus (642 genes); S, Hogenesch Kidney (2603 genes); T, Hogenesch Liver (3186 genes); U, Hogenesch Lung (2327 genes); V, Hogenesch Skeletal Muscle (733 genes); W, Hogenesch white fat (856 genes).
Figure 2Venn diagram depicting the overlap of the lists of genes with a circadian expression profile obtained from analysis of gene expression profiles in each of the four sleep conditions tested using our previously reported algorithm 2, 7. Orange plus yellow highlighted area indicates genes that are identified as having a circadian expression profile during 40 hours of wakefulness with and without sufficient sleep. Blue and yellow highlighted area indicates genes that are identified as having a circadian expression profile when sleeping in and out of phase with melatonin. Yellow area indicates genes that are found to have a circadian expression profile across all conditions we have tested in humans, i–iii. Top‐ten biological processes associated with the circadian genes identified in each comparison listed above, respectively. Letters indicate which segments of the Venn contributed to the comparison. The total number of circadian genes identified is given together with the number of rhythmic core clock genes (in brackets). The % enrichment for each process is listed together with the p‐value. The colour‐coded pie chart segments also represent the % enrichment for each process.
Figure 3The z‐scored mRNA expression level (mean ± SEM across subjects) of NR1D2 (A_23_P302709) within human blood during our investigations of A: chronic and acute sleep loss, B: forced desynchrony. Shaded grey area indicates the corresponding average (across subjects) plasma melatonin profile. Horizontal bars indicate wake (w) and sleep (s) periods. The figure shows that the expression profile of NR1D2 remains relatively unchanged in response to both insufficient sleep (A) and mistimed sleep (B) with a peak of expression close to the peak of melatonin secretion.
Figure 4The z‐scored mRNA expression level (mean ± SEM across subjects) of NR1D1 (A_23_P420873) within human blood during our investigations of A: chronic and acute sleep loss, B: forced desynchrony. Shaded grey area indicates the corresponding average (across subjects) plasma melatonin profile. Horizontal bars indicate wake (w) and sleep (s) periods. The figure shows that the expression profile of NR1D1 remains relatively unchanged in response to both insufficient sleep (A) and mistimed sleep (B) with a peak of expression close to the peak of melatonin secretion.
Human genes characterized as robustly rhythmic in human blood and their rhythmicity in other samples
| Human samples | Mouse samples | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human gene symbol | Mouse gene symbol | Total human lists | Total mouse lists | Percent of all human samples % | Percent of human Blood samples % | Percent of all mouse samples % | Percent of all samples % | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
| NR1D2 | Nr1d2 | 6 | 16 | 86 | 100 | 100 | 96 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SLC6A6 | Slc6a6 | 5 | 8 | 71 | 100 | 50 | 57 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 |
| FAM126B | Fam126b | 4 | 6 | 57 | 100 | 38 | 43 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 0 |
| MPZL1 | Mpzl1 | 4 | 6 | 57 | 100 | 38 | 43 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| HNRPDL | Hnrpdl | 4 | 5 | 57 | 100 | 31 | 39 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| TMEM140 | Tmem140 | 4 | 5 | 57 | 100 | 31 | 39 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| B4GALT5 | B4galt5 | 6 | 2 | 86 | 100 | 13 | 35 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| GCA | Gca | 4 | 4 | 57 | 100 | 25 | 35 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| CSNK1E | Csnk1e | 5 | 2 | 71 | 100 | 13 | 30 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| CCNJL | Ccnjl | 4 | 3 | 57 | 100 | 19 | 30 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| ST6GALNAC2 | St6galnac2 | 4 | 3 | 57 | 100 | 19 | 30 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| ADM | Adm | 4 | 2 | 57 | 100 | 13 | 26 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| BCL2 | Bcl2 | 4 | 2 | 57 | 100 | 13 | 26 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| SLC22A4 | Slc22a4 | 4 | 2 | 57 | 100 | 13 | 26 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| GK | Gyk | 4 | 1 | 57 | 100 | 6 | 22 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MAL | Mal | 4 | 1 | 57 | 100 | 6 | 22 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| ALOX5AP | Alox5ap | 4 | 0 | 57 | 100 | 0 | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AVIL | Avil | 4 | 0 | 57 | 100 | 0 | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CNTNAP3 | Cntnap3 | 4 | 0 | 57 | 100 | 0 | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DAAM2 | Daam2 | 4 | 0 | 57 | 100 | 0 | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NELL2 | Nell2 | 4 | 0 | 57 | 100 | 0 | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NFAM1 | Nfam1 | 4 | 0 | 57 | 100 | 0 | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| OTX1 | Otx1 | 4 | 0 | 57 | 100 | 0 | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| TREM1 | Trem1 | 4 | 0 | 57 | 100 | 0 | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A_24_P725998 | NA | 4 | NA | 57 | 100 | NA | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| A_32_P133564 | NA | 4 | NA | 57 | 100 | NA | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HCG27 | NA | 4 | NA | 57 | 100 | NA | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CREB5 | Creb5 | 4 | NA | 57 | 100 | NA | 17 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Key for samples: A, Akashi follicle (240 genes), B, Archer Sleeping in Phase (1,395 genes); C, Archer Sleeping out of Phase (228 genes); D, Hughes (1,111 genes); E, Li Human brain (916 genes); F, Moller‐Levet Sleep Extension (1,855 genes); G, Moller‐Levet Sleep Restriction (1,480 genes); H, Barclay rhythmic control classes 1, 2, and 3 (3,231 genes); I, Barclay rhythmic Total Sleep Restriction classes 1, 2, and 6 (2,461 genes); J, Maret Table3 Control Condition (1,654 genes); K, Maret Table 4 Sleep Deprivation (340 genes); L, Hogenesch Adrenal gland (1,052 genes); M, Hogenesch Aorta (873 genes); N, Hogenesch BrainStem (693 genes); O, Hogenesch Brown fat (1,492 genes); P, Hogenesch Cerebellum (726 genes); Q, Hogenesch Heart (1,187 genes); R, Hogenesch Hypothalamus (642 genes); S, Hogenesch Kidney (2,603 genes); T, Hogenesch Liver (3,186 genes); U, Hogenesch Lung (2,327 genes); V, Hogenesch Skeletal Muscle (733 genes); W, Hogenesch white fat (856 genes).
Figure 5Direct interaction networks, as documented by MetaCoreTM, between genes for which at least one transcript had a statistically significant main effect of sleeping in‐phase and out‐of‐phase with melatonin (A), or a main effect one week of either sufficient or insufficient sleep prior to a 40 hours period of total sleep deprivation (B). Node size reflects the number of direct connections a gene has within the network. Node color (see key) represents the most significantly enriched GO biological process term associated with that node given the submission of the statistically significant gene lists to the tool WebGestalt. The figures identify networks of genes that are affected by sleep disruption that also show high levels of interactivity. Some interacting genes are common to both sleep disruption conditions, and a large number are linked with processes known to be associated with adverse health outcomes (see text for details).